[1] CHEN M, YANG Q, XU Z, et al. Survival analysis and prediction model for pulmonary sarcomatoid carcinoma based on SEER database[J]. Front Oncol, 2021, 11: 630885.
[2] SUN L, DAI J, CHEN Y, et al. Pulmonary sarcomatoid carcinoma: experience from SEER database and Shanghai Pulmonary Hospital[J]. Ann Thorac Surg, 2020, 110(2): 406-413.
[3] NAGANO M, KOHSAKA S, HAYASHI T, et al. Comprehensive molecular profiling of pulmonary pleomorphic carcinoma[J]. NPJ Precis Oncol, 2021, 5(1): 57.
[4] STEPHAN-FALKENAU S, STREUBEL A, MAIRINGER T, et al. Integrated clinical, molecular and immunological characterization of pulmonary sarcomatoid carcinomas reveals an immune escape mechanism that may influence therapeutic strategies[J]. Int J Mol Sci, 2023, 24(13): 10558.
[5] 蒋兰, 杨匹容, 李娟. 肺肉瘤样癌的治疗进展[J]. 肿瘤预防与治疗, 2023, 36(9): 753-758.
[6] OIZUMI S,TAKAMURA K,HARADA T,et al. Phase Ⅱ study of carboplatin-paclitaxel alone or with evacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024[J].Int J Clin Oncol,2022,27(4):676-683.
[7] LI J, LIANG H, HE J, et al. Anlotinib combined with chemotherapy for recurrence of pulmonary sarcomatoid cancer previously surgically treated: a case report and literature review[J]. Front Oncol, 2021, 11: 639168.
[8] SAWATARI K, IZUMI M, SONE R, et al. A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab[J]. Respir Med Case Rep, 2022, 36: 101579. |
